Bioinformatics Solutions, Inc. Chooses Science Exchange as the Primary Online Channel to Offer Protein de novo Sequencing Services to Scientists

December 11, 2017 | Posted by Team in Lab Profiles, New Innovations, Press Release, Research |

BSI Science Exchange Partnership

PALO ALTO, CA, December 11, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced the partnership with Bioinformatics Solutions, Inc. to offer online access to its protein de novo sequencing services to scientists around the globe.

As the creators of the well-known, highly established PEAKS Software, the golden standard of de novo sequencing, Bioinformatics Solutions, Inc., offers their de novo sequencing expertise to scientists at a new level by sequencing the samples themselves.

“Bioinformatics Solutions, Inc. has developed a proprietary de novo protein sequencing workflow to retrieve the amino acid sequence of an unknown antibody protein with state-of-the-art mass spectrometry techniques. Through this workflow, the sequence assembly is purely based on de novo sequencing. Therefore, no database, cDNA, mRNA, or hybridoma cell line is required,” exclaims Baozhen Shan, CEO of Bioinformatics Solutions, Inc. “With constant ongoing research at Bioinformatics Solutions, Inc., the advanced technology will ensure our service delivers a highly accurate sequence, identification of sequence variants, glycosylations, and unknown modifications.  By partnering with Science Exchange, these sequencing services will now be available to researchers all over the world to help them make breakthrough discoveries.”

Over the last few years, Science Exchange has undergone extensive growth and recently received a $28 million in Series C funding led by Norwest Venture Partners. By continuing to team up with companies like Bioinformatics Solutions, Inc. Science Exchange is providing researchers worldwide with access to the most important scientific services to advance their experiments.

“We are excited to partner with Bioinformatics Solutions, Inc. to make available its protein de novo sequencing services to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists have the services they need securely and readily available to aid their discoveries. Bioinformatics Solutions, Inc. met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of proteomics analysis.”

 

About Bioinformatics Solutions, Inc.

For more than 15 years, Bioinformatics Solutions, Inc. has been changing the field of proteomics analysis, by pushing the boundaries of its computational limits and striving to provide groundbreaking research with the customer-first approach. Bioinformatics Solutions, Inc. believes the only solution is one that incorporates quality and timely results, a satisfying product experience, customer support and two-way communication. This diverse and adaptable group is committed to serving the needs of pharmaceutical, biotechnological, and academic scientists; and to the progression of recombinant protein production and drug discovery research. For more information, visit www.scienceexchange.com/labs/bioinformatics-solutions-inc. Follow the company on Twitter @PEAKSProteomics and @PEAKSAB.

Science Exchange Wins Two Gold Stevie® Awards in 2017 Stevie Awards for Women in Business

November 21, 2017 | Posted by Team in Company, Press Release, Science Exchange News |

Dr. Elizabeth Iorns Honored as Female Entrepreneur of the Year and Science Exchange as Most Innovative Company of the Year

Gold Stevie Award 2017 Science Exchange

Palo Alto, CA – November 21, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced that CEO and Co-Founder Dr. Elizabeth Iorns, has been named the winner of the Gold Stevie® Award for Female Entrepreneur of the Year. In addition, Science Exchange has been named Most Innovative Company of the Year at the 14th annual Stevie Awards for Women in Business.

The Stevie Awards for Women in Business are the world’s top honors for female entrepreneurs, executives, employees and the organizations they run. The 2017 awards received over 1500 entries from 25 nations and territories; winners were recognized at a November 17 event in New York City.

Dr. Elizabeth Iorns founded Science Exchange in 2011 and has built a global company that has raised over $58M in venture funding. Dr. Iorns has led Science Exchange to rapid growth with enterprise partnerships with the most innovative R&D focused Fortune 100 companies. Science Exchange provides a technology platform for efficient access to the world’s best external R&D partners. Through Science Exchange, scientists can instantly connect and order outsourced scientific projects from over 2,500 top research facilities available under the Science Exchange contract.

“I am honored to receive the Stevie award and be recognized among other inspiring women and companies around the world,” said Dr. Elizabeth Iorns, co-founder and CEO of Science Exchange. “I am also extremely proud of the teams at Science Exchange that work tirelessly with our clients on their outsourced R&D projects to accelerate scientific discovery.”

“The judges were so impressed with the accomplishments of all of the Stevie Award-winning women and organizations. The 2017 Stevie Awards for Women in Business received a record number of nominations and had a record number of ceremony attendees,” said Michael Gallagher, founder and president of the Stevie Awards. “We congratulate all of this year’s Grand, Gold, Silver and Bronze Stevie Award winners for their achievements.”

Details about the Stevie Awards for Women in Business and the list of Stevie Award winners are available at www.StevieAwards.com/Women.  

 

Science Exchange Announces Outsourced R&D Partnership with Alector

November 20, 2017 | Posted by Team in Company, Drug Discovery, Outsourcing Best Practices, Press Release, Science Exchange News |

Science Exchange-Alector PartnershipPALO ALTO, Calif.–Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.

“The Science Exchange platform solves the challenges of R&D outsourcing: we provide scientists with efficient access to a diverse network of qualified suppliers under a single relationship, and at the same time we provide sourcing departments with more information and control over their outsourcing spend,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be the provider of Alector’s R&D marketplace and help bring potential treatments for Alzheimer’s disease to patients more quickly and efficiently. Especially following the exciting news on Alector’s partnership with AbbVie to advance therapies for Alzheimer’s disease, it’s clear that Alector has extremely promising drug targets — we’re honored to help accelerate these important discoveries.”

The Science Exchange-powered R&D marketplace enables scientists to instantly order more than 6,000 unique scientific services from the 2,500 CROs, academic labs, and government facilities that are available under a single Science Exchange contract. The partnership also will provide Alector with a platform to effectively manage the company’s outsourced R&D investments, including the ability to track supplier utilization, trends, and performance, which also supports the need for compliance with internal policies and external regulations.

Alector is the latest R&D company to choose to partner with Science Exchange, and joins more than 30 enterprise organizations, including 10 of the top 20 pharma companies, that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for connecting with a broad network of qualified scientific service providers,” said Arnon Rosenthal, Ph.D., co-founder and CEO of Alector. “It is our hope that working with Science Exchange will enable us to more quickly advance discovery and development of novel immuno-neurology therapies.”

Under the agreement, Science Exchange will support company-specific governance, approval workflows, and preferred vendors. To minimize the risk frequently associated with outsourcing to external service providers, the Science Exchange guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by a best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated work.

 

Visit www.scienceexchange.com/enterprise to request a demo of our award-winning private marketplaces for managing outsourced research and development!

Elizabeth Iorns, Ph.D., CEO of Science Exchange Elected to the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT)

November 15, 2017 | Posted by Team in Press Release |

Elizabeth Iorns elected to DCAT Board

PALO ALTO, CA, November 15, 2017 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced today that Elizabeth Iorns, Ph.D., CEO of Science Exchange, has been elected to serve her first term on the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT) beginning November 1, 2017.  Members of DCAT’s Board of Directors are charged with the important work of guiding the organization’s strategic initiatives and activities.

“We are delighted to have Dr. Iorns join the Board of Directors,” said DCAT Executive Director Margaret Timony. “She brings a unique mix of leadership experiences that will add a valuable perspective to the board.”

“I am honored to join the board and work together with this great team to address key initiatives related to the pharmaceutical industry,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Our mission at Science Exchange is to help accelerate innovation and scientific discoveries, and as a scientist myself, I feel joining DCAT’s board is a perfect opportunity for me to share my ideas and insights to support and advance its programs and services.”

About DCAT

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.

 

Explore Science Exchange’s network of qualified service providers for:

 

 

Science Exchange Scientific Provider Elion Labs Presenting New Research at the AAPS Annual Meeting

November 13, 2017 | Posted by Team in Drug Discovery, Events, New Innovations, Press Release, Research |
  • Breakthrough in drug product particle analysis using machine learning

  • Biopharma researchers can access Elion’s new services from scienceexchange.com

Science Exchange and Elion at AAPS

PALO ALTO, CA, and LOUISVILLE, CO, November 13, 2017 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development, is proud to announce that Elion Labs, provider of analytical development and drug product characterization services, will present exciting new research at the 2017 AAPS (American Association of Pharmaceutical Scientists) Annual Meeting, the most comprehensive event for innovations in bioanalysis, formulation, and product characterization.

Elion’s expertise has helped bring numerous clinical products to market. Their AAPS research poster presentation (Abstract M8003) introduces a novel method for drug product analysis, using machine learning and advanced image analysis to improve particle detection, enumeration, and classification.

“Machine learning approaches open up exciting new possibilities for analyzing particles in biologics, and ultimately, for better analyzing a broad range of complex data sets,”  said John Gabrielson, Ph.D., CEO and Founding Partner of Elion Labs. “We hope that our research will help biopharmaceutical researchers develop safer, more effective drugs and deliver them to patients faster.”

Elion and Science Exchange will exhibit at booth 2337 at AAPS, meeting drug discovery and development researchers and representatives of regulatory agencies seeking the latest, innovative services available for pharmaceutical analysis.

“We’re proud to participate in this year’s conference alongside Elion, who are true thought leaders in analytical research,” said Elizabeth Iorns, Ph.D., CEO and Co-Founder of Science Exchange. “And because they’re part of the Science Exchange network, biopharmaceutical researchers can access Elion’s technologies immediately under our pre-existing master service agreement that covers IP and confidentiality.”

More information about Elion Labs and their innovative services can be found at www.scienceexchange.com/labs/elion-labs.

 

About Elion Labs

Elion Labs, based in Louisville, Colorado, USA, was founded to serve the analytical development and product characterization needs of the biopharmaceutical industry. Elion offers a variety of services, including analytical method development, qualification and validation; analytical characterization testing of biologics; formulation development; training in highly specialized analytical techniques; comprehensive data analysis including visualization and interpretation of complex data sets; technical and regulatory writing; and technical consulting. They are committed to providing all services with unmatched professionalism, quality, and speed.

About Science Exchange

Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

 

 

Science Exchange Announces New Director of Scientific Content, Gursatya “Guru” Singh

November 2, 2017 | Posted by Team in Press Release, Science Exchange News |

Guru Singh Science Exchange

PALO ALTO, CA, November 2, 2017Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that Gursatya “Guru” Singh has joined the company’s management team as Director of Scientific Content.

“Adding Guru to our team is part of our ongoing commitment to strengthen the management team with industry experts who are dedicated to disrupting the traditional R&D outsourcing model,” said Elizabeth Iorns, Ph.D., CEO and co-founder of Science Exchange. “Guru’s experience in this industry will help us better inform the scientific community about the benefits of accessing innovation through the Science Exchange platform.”

Singh’s background includes experience as a laboratory researcher and entrepreneur, as he has helped launch several life science startups. This included a previous role where he developed scientific content to promote the innovative services and technologies of scientific service providers. Singh also has published several scientific papers.

A frequent blogger and thought leader in pharma and biotech outsourcing, Singh founded a Facebook group – Mysteries of Biotech – that has amassed nearly 5,000 followers. He holds a master’s degree in biotechnology from the University of Delaware and a bachelor’s degree in biotechnology from Sharda University in India.

“I am excited to join Science Exchange — the most trusted outsourcing platform for scientific products and services,” said Singh. “Science Exchange is a trailblazing company that is revolutionizing R&D outsourcing by helping companies around the world bring their innovations to market faster. I can’t think of a better place to be.”

Elizabeth Iorns, Ph.D., Named 2017 Scrip Award Executive of the Year Finalist

November 1, 2017 | Posted by Team in Company, Events, Press Release, Science Exchange News |

Scrip Award Finalist Elizabeth Iorns

PALO ALTO CA, November 1, 2017 –  Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that company CEO and co-founder Elizabeth Iorns, Ph.D., has been selected as an Executive of the Year finalist in the prestigious 2017 Scrip Awards.

Dr. Iorns is one of six C-level executives recognized in the Executive of the Year category for private companies or those with a market capitalization of <$1 billion. This awards category acknowledges excellence in the leadership of large and small pharmaceutical and biotechnology companies around the world.

A cancer researcher herself, Iorns co-founded Science Exchange in 2011 to streamline R&D outsourcing and facilitate access to qualified, innovative scientific service providers. Because of the robust platform’s clear benefits to R&D organizations, she has successfully negotiated enterprise-level agreements between Science Exchange and many of the world’s top biopharma companies, as well as with numerous biotech and pharma startup incubators. Over the past year, in addition to expanding the company’s reach into other R&D reliant industries like agrisciences and cosmetics, Iorns led the a successful Series C venture capital funding round, bringing an additional $28 million of investment that will allow Science Exchange to accelerate its impressive growth.

Iorns is also the co-director of the Reproducibility Initiative, and is a part-time partner at Y Combinator. She has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK), and before starting Science Exchange was an Assistant Professor at the University of Miami, where she remains an Adjunct Professor. She has been recognized previously as one of Nature’s “Ten People that Mattered” and WIRED’s “50 Women Who Are Changing The World.”

In its 13th year, the Scrip Awards program recognizes the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. A panel of 16 highly respected and independent experts from across diverse sectors evaluated the award entries to select the finalists. The winners across 16 categories will be announced at the 13th Annual Scrip Awards ceremony at the London Hilton on Park Lane in London, England on November 29, 2017. For more details on the event, visit www.ScripAwards.com.  

iSpecimen and Science Exchange Announce Technology Integration to Allow Instant Access to Human Biospecimens

October 24, 2017 | Posted by Team in Company, Press Release, Science Exchange News |

Scientists in search of human biospecimens can now search the iSpecimen Marketplace via Science Exchange as part of one seamless experience

LEXINGTON, Mass. and PALO ALTO, Calif.Oct. 24, 2017 /PRNewswire/ —iSpecimen and Science Exchange today announced a marketplace technology integration that will allow Science Exchange users to directly search for biospecimens available in the iSpecimen Marketplace via a single user interface.

Science Exchange is the world’s leading and most secure platform for outsourced research and development (R&D) services, and the iSpecimen Marketplace is the premier online platform instantly connecting life science researchers in need of human biospecimens with the healthcare organizations that have them. By integrating these two solutions, Science Exchange users will now have access in real time to more than 25 million banked and prospectively collected specimens, including biofluids, solid tissue, and cells, all available on the iSpecimen Marketplace.

“iSpecimen shares our commitment to accelerating breakthrough scientific discovery through innovative technology,” said Elizabeth Iorns, PhD, Founder and CEO, Science Exchange. “With the seamless integration of the iSpecimen Marketplace and Science Exchange platform, our users gain direct, on-demand access to millions of human biospecimens.”

While iSpecimen has been available through Science Exchange since 2014, the new integration minimizes the time and complexity involved with specimen procurement. Additionally, the legal and compliance infrastructure in place for Science Exchange users reduces the risks often associated with biospecimen procurement. In the iSpecimen Marketplace, researchers have instant access to compliance documentation on a per specimen basis, giving researchers assurance before obtaining specimens that their requested samples were ethically sourced with appropriate regulatory oversight.

“The drive towards precision medicine is advancing the pace of research and increasing the need for biospecimens and related services,” said Christopher Ianelli, MD, PhD, Founder and CEO, iSpecimen. “The integration of the iSpecimen Marketplace into the Science Exchange environment accelerates research by giving scientists broader access to specimens from within the world’s leading platform for outsourced scientific services. We are honored to be working with Science Exchange in this way.”

Researchers interested in iSpecimen and Science Exchange can learn more and see demonstrations this week at ProcureCon Pharma in Philadelphia, where both Ianelli and Iorns will be speaking as part of a plenary panel.

QB3 Signs Partnership with Science Exchange

October 23, 2017 | Posted by Team in Company, Press Release, Science Exchange News |

Qb3 Partners With Science ExchangeBay Area Life Science Hub Enables its Startups to Stay Lean with Science Exchange’s R&D Platform

PALO ALTO, CA, October 23, 2017Science Exchange, a platform for outsourced research and development (R&D) services, today announced a partnership with QB3, the University of California hub for innovation and entrepreneurship for life sciences.

Through an exclusive Science Exchange-QB3 marketplace, QB3-affiliated companies will now have access to a customized and secure marketplace where they can instantly order R&D services from a network of more than 2,500 qualified scientific service providers. Science Exchange’s scientific concierge staff also will offer support to QB3’s start-up companies in identifying innovative providers and ordering complex R&D services.

“Science Exchange will help accelerate our companies by giving them access to providers that are experienced with entrepreneurial research and that have already been reviewed and qualified,” said Ioana Aanei, Ph.D., Entrepreneurship Program Manager at QB3. “Many of our startups don’t have the resources to purchase their own capital equipment or do the necessary specialized scientific research in-house.”

“Science Exchange is committed to helping life science companies bring innovative, potentially life-saving products to market,” said Elizabeth Iorns, Ph.D., Founder & CEO of Science Exchange. “While QB3’s companies focus on discovery, we can help eliminate the barriers, including the time and expertise needed to research and qualify contract research organizations (CROs) and scientific service providers. We also help save time and money in contract negotiation, all while ensuring the protection of intellectual property.”

QB3 joins more than 30 enterprise clients and entrepreneurial incubators that are efficiently managing their outsourced R&D with Science Exchange-powered marketplaces.

About QB3

QB3 is the University of California’s hub for innovation and entrepreneurship in the life sciences. The institute supports UC researchers and empowers Bay Area entrepreneurs to launch startup companies and partner with industry. QB3 helps bio-entrepreneurs create hundreds of high-value jobs and bring more than $750 million into the Bay Area each year. With campus divisions at Berkeley, San Francisco, and Santa Cruz, QB3 is also affiliated with the San Francisco incubator QB3@953 — home to more than 45 companies — and the seed-stage venture capital firm Mission Bay Capital. Visit us at http://qb3.org/.

 

Science Exchange Honored by Goldman Sachs for Entrepreneurship

October 19, 2017 | Posted by Team in Company, Events, Press Release, Science Exchange News |

Co-Founder and CEO Elizabeth Iorns Among 100 Most Intriguing Entrepreneurs at 2017 Builders + Innovators Summit

Palo Alto, CA – October 19, 2017 – Goldman Sachs (NYSE:GS) is recognizing Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange as one of the 100 Most Intriguing Entrepreneurs of 2017 at its Builders + Innovators Summit in Santa Barbara, California.

Goldman Sachs selected Elizabeth as one of 100 entrepreneurs from multiple industries to be honored at the two-day event.

The life sciences research community has been transformed by Elizabeth’s ability to execute upon her vision to transform the procurement and delivery of outsourced R&D services. Thanks to her tenacity and drive, and her deep understanding of the need for improved R&D efficiency, Science Exchange is enabling breakthrough scientific discoveries by providing researchers with an online platform for efficient access to the world’s best outsourced R&D service providers.

“This is a tremendous honor and I’m excited to be recognized by Goldman Sachs along with these other inspiring entrepreneurs,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “The work our team at Science Exchange has been doing in outsourced R&D is critical for driving scientific breakthroughs and innovation and I’m proud to lead the team in this charge.”

“We are pleased to recognize Elizabeth Iorns as one of the most intriguing entrepreneurs of 2017,” said David M. Solomon, President and Co-Chief Operating Officer at Goldman Sachs. “This is the sixth year that we’ve hosted the Builders + Innovators Summit where emerging business leaders gather to discuss their common interests in building prosperous organizations.”

For more than 145 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the Summit consists of general sessions and clinics led by Goldman Sachs experts, seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Elizabeth Iorns

Elizabeth Iorns, Ph.D., is the CEO and Founder of Science Exchange. Elizabeth Iorns has transformed scientific research by radically improving the procurement and delivery of outsourced research and development (R&D) services. Elizabeth Iorns, Ph.D. (Institute of Cancer Research, London) was an Assistant Professor at University of Miami’s Miller School of Medicine, where she investigated breast cancer development and progression, before launching Science Exchange in 2011. Elizabeth’s work has been featured in multiple media outlets, and she regularly speaks at thought leadership events, such as the 2017 TechCrunch Disrupt event in San Francisco, 2017 Society for Laboratory Automation and Screening annual meeting and the 2016 MassBio CRO/CMO Symposium. Her recent honors include Nature’s “Ten People that Mattered,” WIRED’s “50 Women Who Are Changing The World,” and the “Kauffman Foundation Emerging Entrepreneur Award.” She is a finalist for 2017 Scrip Executive of the Year Award.

About Science Exchange
Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com